New Approvals in Low- and Intermediate-Risk Myelodysplastic Syndromes
Recent advances in defining low- and intermediate-risk myelodysplastic syndromes myelodysplastic syndromes: (my-eh-lo-diss-PL
Myelodysplastic Syndromes (MDS)
Michael S. Samuel, MD
Institution
Weill Cornell Medicine
Physician Status
accepting new patients
Primary Disease Area of Focus
Acute Myeloid Leukemia (AML)
Myelodysplastic Syndromes (MDS)
Myeloproliferative Neoplasms (MPN)
Jeanne M. Palmer, MD
Institution
Mayo Clinic, Phoenix, AZ
Physician Status
accepting new patients
Primary Disease Area of Focus
Graft Versus Host Disease (GVHD)
Myelodysplastic Syndromes (MDS)
Myeloproliferative Neoplasms (MPN)
Yeung Chul Mun, MD
Institution
Ewha Woman's Medical Center Seoul Hospital
Primary Disease Area of Focus
Myelodysplastic Syndromes (MDS)
Adriana K Malone, MD
Institution
Icahn School of Medicine at Mount Sinai
Physician Status
accepting new patients
Primary Disease Area of Focus
Acute Myeloid Leukemia (AML)
Myelodysplastic Syndromes (MDS)
Myeloproliferative Neoplasms (MPN)
Leo Luznik, MD
Institution
Johns Hopkins University
Physician Status
accepting new patients
Primary Disease Area of Focus
Acute Myeloid Leukemia (AML)
Chronic Lymphocytic Leukemia (CLL)
Graft Versus Host Disease (GVHD)
Myelodysplastic Syndromes (MDS)
Sydney X. Lu, MD
Institution
Stanford University School of Medicine
Physician Status
accepting new patients
Primary Disease Area of Focus
Acute Myeloid Leukemia (AML)
Chronic Lymphocytic Leukemia (CLL)
Myelodysplastic Syndromes (MDS)
Taking Charge of My Care and Advocacy Following a Cancer Diagnosis
Original Publication Date
Article Source
External Web Content
After a long battle with illness and seeking many specialists, I emphasize the need to self-advocate for ongoing care following my cancer diagnosis. Almost every cancer survivor will agree that we end up going to too many doctors. A friend of mine with both cancer and diabetes…
The impact of ABO compatibility on allogeneic hematopoietic cell transplantation outcomes: a contemporary and comprehensive study from the transplant complications working party of the EBMT
Original Publication Date
Article Source
External Web Content
Abstract The role of ABO blood group system mismatch on allogeneic hematopoietic cell transplantation (allo-HCT) outcomes is controversial since current publications of large datasets are lacking. We retrospectively analyzed 30,487 patients transplanted between 2010 and 2021…
Ross L. Levine, MD
Institution
Memorial Sloan-Kettering Cancer Center
Physician Status
accepting new patients
Primary Disease Area of Focus
Acute Myeloid Leukemia (AML)
Myelodysplastic Syndromes (MDS)
Myeloproliferative Neoplasms (MPN)